Navigation Links
SyntheMed Receives US Patent on Novel Polymer Technology
Date:7/30/2009

ISELIN, N.J., July 30 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that it has been awarded US Patent #7,569,643 pertaining to its bioresorbable reverse thermal gelation polymer technology. This represents the latest in a series of patents covering this novel technology and pertains to the application of these materials in the reduction of post-operative adhesion formation. Dr. Eli Pines, the Company's Vice President and Chief Scientific Officer stated, "The novelty of these materials is that they can be delivered to difficult to access sites in the body as a liquid through a syringe or as a spray and, once exposed to body temperature, rapidly transition to a resorbable, adherent, high viscosity gel. Thus, they are ideally suited as anti-adhesion materials in spine and tendon surgery."

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.

Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain FDA and other required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination
2. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
3. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. SyntheMed Announces New Management Appointments
6. SyntheMed Completes $4.0 Million Equity Placement
7. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
8. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
9. SyntheMed Files Universal Shelf Registration
10. SyntheMed to Present at the Acumen BioFin Conference
11. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit ... are researched, developed, marketed and made accessible to patients around ... Open had named the publication of the Good ... The publication is also featured as one of BMJ ... the last year that are most frequently read. ...
(Date:2/11/2016)... 11, 2016  Wellcentive today announced it has ... Oregon -based community care organization (CCO) with ... analytics, quality reporting and care management solutions and ... team of quality managers, analysts and care managers ... groups serving FamilyCare members. ...
(Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... BioInformant announces the February 2016 release of its ... and Technologies – Market Size, Segments, Trends, and Projections ... The first and only market research firm ... more than a decade of historical information on all ... type. This powerful 175 page global strategic report contains ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):